---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277985"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:27:57.406464+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aeglea recasts FY2022 financials for 1-for-25 reverse split; going concern warning persists

## Summary
- 1-for-25 reverse stock split effective Sept 8, 2023; authorized shares cut from 500M to 20M.
- Recast FY2022 net loss $83.8M ($24.86/share) on total revenue of $2.3M.
- Accumulated deficit $425.6M as of Dec 31, 2022; cash & securities $57.3M.
- Substantial doubt about going concern; cash expected to fund only into Q4 2023.
- Auditor's opinion includes going concern emphasis paragraph.

## SEC filing metadata
- accession: 0001193125-23-277985
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523277985/0001193125-23-277985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523277985/d361815d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277985
- JSON: https://secwatch.observer/filing/0001193125-23-277985.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.